|
gptkbp:instanceOf
|
clinical guideline
|
|
gptkbp:appliesTo
|
incidental findings
|
|
gptkbp:contains
|
list of 59 genes
|
|
gptkbp:documentType
|
policy statement
|
|
gptkbp:focusesOn
|
actionable genes
|
|
gptkbp:fullName
|
American College of Medical Genetics and Genomics Secondary Findings v2.0
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ACMG SF v2.0
|
|
gptkbp:language
|
English
|
|
gptkbp:precededBy
|
gptkb:ACMG_SF_v3.0
|
|
gptkbp:publicationYear
|
2017
|
|
gptkbp:publishedBy
|
gptkb:American_College_of_Medical_Genetics_and_Genomics
|
|
gptkbp:purpose
|
recommendations for reporting secondary findings in clinical exome and genome sequencing
|
|
gptkbp:recommendsReporting
|
pathogenic variants in specified genes
|
|
gptkbp:replacedBy
|
gptkb:ACMG_SF_v1.0
|
|
gptkbp:targetAudience
|
healthcare providers
clinical laboratories
medical geneticists
|
|
gptkbp:updated
|
expanded gene list compared to v1.0
|
|
gptkbp:usedIn
|
clinical genomics
|
|
gptkbp:bfsParent
|
gptkb:ACMG_recommendations_for_reporting_of_incidental_findings_in_clinical_exome_and_genome_sequencing
|
|
gptkbp:bfsLayer
|
7
|